Alterity Therapeutics Secures US Patent Extending ATH434 Protection to 2045
Alterity Therapeutics has won a new US composition of matter patent for its lead drug ATH434, extending intellectual property protection to at least 2045 and boosting its commercial potential ahead of Phase 3 trials in Multiple System Atrophy.
- New US patent covers crystalline mesylate form of ATH434
- Patent extends protection to at least 2045
- Strengthens IP ahead of Phase 3 trial initiation in MSA
- Enables future ATH434 development for Parkinson’s disease
- Supports strategic value and potential partnerships
Patent Boosts ATH434’s Commercial Lifespan
Alterity Therapeutics (ASX:ATH, NASDAQ: ATHE) has secured a significant intellectual property win with the United States Patent and Trademark Office granting a new composition of matter patent for its lead clinical candidate ATH434. This patent extends protection for ATH434 to at least 2045, a move that markedly enhances the drug’s long-term commercial prospects as the company prepares to launch Phase 3 trials in Multiple System Atrophy (MSA) by year-end 2026.
Crystalline Mesylate Form Underpins Protection
The patent covers a crystalline form of the mesylate salt of ATH434, the exact formulation used in Alterity’s Phase 2 clinical trials and planned for Phase 3 studies. It also protects methods for treating neurological disorders with this compound. Composition of matter patents are considered among the strongest pharmaceutical IP protections, safeguarding the drug’s unique chemical structure and therapeutic application.
Strategic Implications for Neurodegenerative Diseases
Beyond MSA, this patent opens the door for future development of ATH434 in Parkinson’s disease and other neurodegenerative conditions characterised by iron dysregulation and protein aggregation. CEO David Stamler highlighted that the strengthened IP portfolio makes Parkinson’s disease a viable target indication, supporting investment in this larger market opportunity.
This development dovetails with Alterity’s recent regulatory progress, including FDA endorsement of a single pivotal Phase 3 trial for ATH434 in MSA, which is on track to commence by late 2026. The company’s Phase 2 data demonstrated clinically meaningful efficacy and a favourable safety profile, underpinning confidence in ATH434’s potential.
Market Protection and Future Partnerships
The patent is expected to be listed in the FDA’s Orange Book upon regulatory approval, adding a further layer of market exclusivity. Alongside existing Fast Track and Orphan Drug designations, this multi-layered protection enhances ATH434’s attractiveness for potential partnerships and commercial deals.
Alterity’s focus remains on advancing ATH434 as a disease-modifying therapy for MSA, a rare and rapidly progressive disorder with no current treatments that slow progression. The company’s progress on both the clinical and IP fronts positions it well to capitalise on unmet needs in neurodegenerative diseases.
Bottom Line?
This patent milestone extends ATH434’s commercial runway and legitimises expansion into Parkinson’s disease, setting the stage for critical Phase 3 developments.
Questions in the middle?
- How will the new patent influence Alterity’s partnering and financing strategies?
- What are the key regulatory milestones to watch as Phase 3 trial activities ramp up?
- How might ATH434’s IP protection compare with competitors targeting neurodegenerative diseases?
